Esther Ellen Freeman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma, Kaposi | 16 | 2024 | 374 | 7.200 |
Why?
|
Dermatology | 21 | 2024 | 914 | 6.340 |
Why?
|
Skin Diseases | 14 | 2023 | 1088 | 5.130 |
Why?
|
Chilblains | 5 | 2022 | 16 | 3.210 |
Why?
|
HIV Infections | 27 | 2024 | 17275 | 1.600 |
Why?
|
Registries | 16 | 2022 | 8175 | 1.550 |
Why?
|
Drug Eruptions | 2 | 2021 | 335 | 1.200 |
Why?
|
Mentors | 2 | 2024 | 660 | 1.130 |
Why?
|
Kenya | 9 | 2024 | 749 | 1.120 |
Why?
|
Coronavirus Infections | 6 | 2020 | 3076 | 1.070 |
Why?
|
Pneumonia, Viral | 6 | 2020 | 3196 | 1.060 |
Why?
|
Blister | 2 | 2023 | 86 | 0.950 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2023 | 2197 | 0.930 |
Why?
|
International Cooperation | 5 | 2024 | 1430 | 0.890 |
Why?
|
Herpes Genitalis | 4 | 2008 | 142 | 0.860 |
Why?
|
Vaccines | 2 | 2021 | 832 | 0.830 |
Why?
|
Lymphangitis | 1 | 2022 | 15 | 0.810 |
Why?
|
Yaws | 1 | 2020 | 3 | 0.750 |
Why?
|
Surgical Equipment | 1 | 2021 | 57 | 0.750 |
Why?
|
Buruli Ulcer | 1 | 2020 | 11 | 0.740 |
Why?
|
Chickenpox | 1 | 2021 | 97 | 0.740 |
Why?
|
Microscopy, Confocal | 3 | 2024 | 1969 | 0.730 |
Why?
|
Elephantiasis, Filarial | 1 | 2020 | 31 | 0.730 |
Why?
|
Skin | 5 | 2023 | 4464 | 0.720 |
Why?
|
Onchocerciasis | 1 | 2020 | 28 | 0.720 |
Why?
|
Leprosy | 1 | 2020 | 125 | 0.710 |
Why?
|
Developing Countries | 4 | 2021 | 2866 | 0.700 |
Why?
|
Exanthema | 2 | 2022 | 504 | 0.690 |
Why?
|
Health Resources | 3 | 2020 | 931 | 0.680 |
Why?
|
Dermoscopy | 1 | 2020 | 66 | 0.680 |
Why?
|
Pemphigoid, Bullous | 1 | 2021 | 114 | 0.670 |
Why?
|
Herpesvirus 2, Human | 4 | 2008 | 191 | 0.670 |
Why?
|
Dermatologic Agents | 2 | 2024 | 308 | 0.660 |
Why?
|
Herpes Simplex | 2 | 2021 | 478 | 0.650 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2020 | 136 | 0.640 |
Why?
|
Herpes Zoster | 1 | 2021 | 251 | 0.640 |
Why?
|
Communicable Diseases, Emerging | 1 | 2020 | 150 | 0.620 |
Why?
|
Herpesvirus 8, Human | 1 | 2020 | 255 | 0.600 |
Why?
|
Social Stigma | 1 | 2024 | 763 | 0.590 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 488 | 0.580 |
Why?
|
Qualitative Research | 3 | 2024 | 2976 | 0.570 |
Why?
|
Urticaria | 3 | 2022 | 150 | 0.560 |
Why?
|
Policy Making | 1 | 2020 | 538 | 0.560 |
Why?
|
Humans | 96 | 2024 | 758406 | 0.530 |
Why?
|
Research Support as Topic | 1 | 2020 | 697 | 0.530 |
Why?
|
Publishing | 1 | 2023 | 833 | 0.510 |
Why?
|
Leadership | 2 | 2024 | 1371 | 0.510 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5404 | 0.500 |
Why?
|
Disease Outbreaks | 7 | 2023 | 1755 | 0.490 |
Why?
|
Community Health Services | 1 | 2020 | 656 | 0.480 |
Why?
|
Pandemics | 10 | 2021 | 8611 | 0.440 |
Why?
|
Bleomycin | 3 | 2022 | 495 | 0.400 |
Why?
|
Skin Neoplasms | 4 | 2021 | 5797 | 0.390 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1201 | 0.380 |
Why?
|
Vincristine | 3 | 2022 | 1038 | 0.360 |
Why?
|
Immunization, Secondary | 2 | 2024 | 368 | 0.360 |
Why?
|
Keratosis, Actinic | 2 | 2021 | 72 | 0.350 |
Why?
|
Vaccination | 7 | 2024 | 3355 | 0.340 |
Why?
|
Biopsy | 2 | 2021 | 6768 | 0.340 |
Why?
|
Herpes Simplex Virus Vaccines | 1 | 2008 | 18 | 0.320 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2014 | 1895 | 0.320 |
Why?
|
Sexual Behavior | 6 | 2012 | 2158 | 0.290 |
Why?
|
Etoposide | 2 | 2022 | 630 | 0.290 |
Why?
|
Africa South of the Sahara | 7 | 2020 | 743 | 0.290 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7378 | 0.270 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2020 | 662 | 0.250 |
Why?
|
Primary Health Care | 3 | 2020 | 4652 | 0.230 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1788 | 0.230 |
Why?
|
Adult | 28 | 2024 | 219935 | 0.230 |
Why?
|
Benzoyl Peroxide | 1 | 2024 | 22 | 0.230 |
Why?
|
Anti-HIV Agents | 2 | 2019 | 4504 | 0.230 |
Why?
|
Hypersensitivity | 2 | 2024 | 1155 | 0.230 |
Why?
|
Salicylic Acid | 1 | 2024 | 63 | 0.230 |
Why?
|
Colposcopy | 1 | 2024 | 150 | 0.220 |
Why?
|
Dicarboxylic Acids | 1 | 2024 | 77 | 0.220 |
Why?
|
Circumcision, Male | 3 | 2011 | 148 | 0.220 |
Why?
|
Severity of Illness Index | 5 | 2022 | 15785 | 0.220 |
Why?
|
Uganda | 3 | 2024 | 1324 | 0.210 |
Why?
|
Administration, Cutaneous | 2 | 2024 | 712 | 0.210 |
Why?
|
Marriage | 1 | 2004 | 350 | 0.210 |
Why?
|
Isotretinoin | 1 | 2024 | 132 | 0.210 |
Why?
|
Delivery of Health Care | 2 | 2017 | 5331 | 0.200 |
Why?
|
Equipment Design | 2 | 2020 | 3507 | 0.200 |
Why?
|
Doxycycline | 1 | 2024 | 341 | 0.200 |
Why?
|
Academies and Institutes | 2 | 2023 | 319 | 0.190 |
Why?
|
Paclitaxel | 2 | 2022 | 1728 | 0.190 |
Why?
|
Middle Aged | 18 | 2024 | 219568 | 0.180 |
Why?
|
Angioedema | 1 | 2022 | 192 | 0.180 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 158 | 0.180 |
Why?
|
Immunophilins | 1 | 2000 | 20 | 0.180 |
Why?
|
Transients and Migrants | 1 | 2023 | 162 | 0.180 |
Why?
|
Consumer Advocacy | 1 | 2020 | 81 | 0.180 |
Why?
|
Spironolactone | 1 | 2024 | 410 | 0.170 |
Why?
|
Male | 29 | 2024 | 358747 | 0.170 |
Why?
|
Authorship | 1 | 2023 | 281 | 0.170 |
Why?
|
Microbiological Techniques | 1 | 2020 | 98 | 0.170 |
Why?
|
Disease Progression | 3 | 2023 | 13468 | 0.170 |
Why?
|
Incidence | 7 | 2020 | 21272 | 0.170 |
Why?
|
Female | 27 | 2024 | 390323 | 0.170 |
Why?
|
Societies, Medical | 2 | 2022 | 3891 | 0.160 |
Why?
|
Acne Vulgaris | 1 | 2024 | 356 | 0.160 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 463 | 0.150 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 328 | 0.150 |
Why?
|
United States | 8 | 2023 | 72136 | 0.150 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 287 | 0.150 |
Why?
|
Biomedical Technology | 1 | 2020 | 209 | 0.150 |
Why?
|
Simplexvirus | 1 | 2021 | 803 | 0.150 |
Why?
|
Photochemotherapy | 2 | 2021 | 820 | 0.150 |
Why?
|
Community Networks | 1 | 2019 | 201 | 0.150 |
Why?
|
Prevalence | 7 | 2021 | 15651 | 0.150 |
Why?
|
Interferon-alpha | 1 | 2022 | 918 | 0.150 |
Why?
|
Doxorubicin | 2 | 2014 | 2209 | 0.140 |
Why?
|
Sexually Transmitted Diseases | 3 | 2008 | 663 | 0.140 |
Why?
|
Drug Therapy, Combination | 3 | 2024 | 6293 | 0.140 |
Why?
|
Retinal Ganglion Cells | 2 | 2000 | 806 | 0.140 |
Why?
|
Cicatrix | 1 | 2023 | 781 | 0.140 |
Why?
|
Optic Nerve | 1 | 2000 | 567 | 0.130 |
Why?
|
Urban Health | 4 | 2007 | 533 | 0.130 |
Why?
|
Tacrolimus | 1 | 2000 | 733 | 0.130 |
Why?
|
Foot | 1 | 2020 | 573 | 0.130 |
Why?
|
Young Adult | 6 | 2024 | 58808 | 0.130 |
Why?
|
Standard of Care | 1 | 2020 | 550 | 0.130 |
Why?
|
Health Facilities | 1 | 2021 | 578 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 611 | 0.130 |
Why?
|
Viral Vaccines | 1 | 2021 | 596 | 0.130 |
Why?
|
Selection, Genetic | 1 | 2020 | 868 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 931 | 0.120 |
Why?
|
Awareness | 1 | 2019 | 644 | 0.120 |
Why?
|
Dermatitis, Atopic | 1 | 2022 | 716 | 0.120 |
Why?
|
Hand | 1 | 2020 | 903 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 748 | 0.120 |
Why?
|
Africa | 3 | 2022 | 706 | 0.120 |
Why?
|
Adolescent | 13 | 2024 | 87892 | 0.120 |
Why?
|
RNA, Messenger | 4 | 2022 | 12759 | 0.120 |
Why?
|
Body Height | 1 | 2020 | 1567 | 0.110 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 61 | 0.110 |
Why?
|
Time Factors | 4 | 2020 | 39872 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5199 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 932 | 0.100 |
Why?
|
Psoriasis | 1 | 2020 | 938 | 0.100 |
Why?
|
Self Report | 1 | 2024 | 3714 | 0.100 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2024 | 2016 | 0.100 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 3671 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2022 | 5484 | 0.100 |
Why?
|
Stochastic Processes | 3 | 2008 | 354 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 512 | 0.100 |
Why?
|
Tretinoin | 1 | 2014 | 519 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13591 | 0.090 |
Why?
|
Biomedical Research | 2 | 2020 | 3418 | 0.090 |
Why?
|
Malawi | 1 | 2012 | 301 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2020 | 2564 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2751 | 0.090 |
Why?
|
Liposomes | 1 | 2014 | 777 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2500 | 0.090 |
Why?
|
Consensus | 1 | 2020 | 3099 | 0.090 |
Why?
|
Review Literature as Topic | 1 | 2012 | 348 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 25956 | 0.090 |
Why?
|
Tuberculosis | 1 | 2023 | 2001 | 0.090 |
Why?
|
Early Detection of Cancer | 1 | 2024 | 3211 | 0.090 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14490 | 0.090 |
Why?
|
World Health Organization | 1 | 2014 | 1312 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3364 | 0.080 |
Why?
|
Risk-Taking | 2 | 2011 | 1034 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1189 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1373 | 0.070 |
Why?
|
HIV Seropositivity | 3 | 2004 | 960 | 0.070 |
Why?
|
Sexual Partners | 1 | 2012 | 791 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 10146 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4158 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2019 | 2159 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11152 | 0.070 |
Why?
|
Risk Factors | 6 | 2021 | 73809 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11709 | 0.070 |
Why?
|
Fluorouracil | 2 | 2021 | 1631 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7403 | 0.060 |
Why?
|
Quality Improvement | 1 | 2020 | 3806 | 0.060 |
Why?
|
Extramarital Relations | 1 | 2004 | 6 | 0.060 |
Why?
|
Benin | 1 | 2004 | 11 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12951 | 0.060 |
Why?
|
Cameroon | 1 | 2004 | 74 | 0.060 |
Why?
|
Cortodoxone | 1 | 2024 | 17 | 0.060 |
Why?
|
Adrenal Cortex Hormones | 2 | 2024 | 1870 | 0.060 |
Why?
|
Tetracyclines | 1 | 2024 | 64 | 0.060 |
Why?
|
Zambia | 1 | 2004 | 257 | 0.060 |
Why?
|
Malta | 1 | 2023 | 6 | 0.060 |
Why?
|
Retinoids | 1 | 2024 | 98 | 0.060 |
Why?
|
Propionates | 1 | 2024 | 182 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8945 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7985 | 0.050 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2024 | 116 | 0.050 |
Why?
|
Injections, Intralesional | 1 | 2024 | 278 | 0.050 |
Why?
|
Minocycline | 1 | 2024 | 168 | 0.050 |
Why?
|
Age Factors | 3 | 2020 | 18358 | 0.050 |
Why?
|
Monkeypox virus | 1 | 2022 | 42 | 0.050 |
Why?
|
Health Policy | 1 | 2014 | 2677 | 0.050 |
Why?
|
Skin Pigmentation | 1 | 2024 | 276 | 0.050 |
Why?
|
Rural Population | 1 | 2012 | 2254 | 0.050 |
Why?
|
Family Practice | 1 | 2004 | 510 | 0.050 |
Why?
|
Hyperventilation | 1 | 2001 | 78 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12440 | 0.050 |
Why?
|
HIV-1 | 2 | 2008 | 6850 | 0.050 |
Why?
|
Diclofenac | 1 | 2021 | 67 | 0.050 |
Why?
|
Chlamydia Infections | 1 | 2004 | 365 | 0.050 |
Why?
|
Microfibrils | 1 | 2020 | 16 | 0.050 |
Why?
|
Nails | 1 | 2022 | 295 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10652 | 0.050 |
Why?
|
Indians, South American | 1 | 2020 | 34 | 0.040 |
Why?
|
Nerve Crush | 1 | 2000 | 76 | 0.040 |
Why?
|
Heredity | 1 | 2020 | 148 | 0.040 |
Why?
|
Sex Factors | 2 | 2020 | 10504 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2000 | 426 | 0.040 |
Why?
|
Advisory Committees | 1 | 2023 | 785 | 0.040 |
Why?
|
Pilot Projects | 2 | 2024 | 8553 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29557 | 0.040 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2000 | 193 | 0.040 |
Why?
|
Hair | 1 | 2022 | 497 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12096 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2022 | 604 | 0.040 |
Why?
|
Nigeria | 1 | 2020 | 762 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2019 | 281 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1040 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14641 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 383 | 0.040 |
Why?
|
Peru | 1 | 2020 | 884 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2017 | 123 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2022 | 64378 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2000 | 1844 | 0.030 |
Why?
|
Cryosurgery | 1 | 2021 | 475 | 0.030 |
Why?
|
Lidocaine | 1 | 1999 | 537 | 0.030 |
Why?
|
Cell Count | 1 | 2000 | 1835 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 3991 | 0.030 |
Why?
|
Public Opinion | 1 | 2019 | 482 | 0.030 |
Why?
|
DNA Primers | 1 | 2000 | 2816 | 0.030 |
Why?
|
Language | 1 | 2024 | 1532 | 0.030 |
Why?
|
Homosexuality | 2 | 1992 | 267 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39059 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3612 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4567 | 0.030 |
Why?
|
Blotting, Western | 1 | 2000 | 5031 | 0.030 |
Why?
|
Information Dissemination | 1 | 2019 | 1129 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4540 | 0.020 |
Why?
|
Bisexuality | 1 | 1992 | 286 | 0.020 |
Why?
|
Age Distribution | 2 | 2008 | 2882 | 0.020 |
Why?
|
Self Care | 2 | 1992 | 794 | 0.020 |
Why?
|
Public Health | 1 | 2022 | 2658 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2204 | 0.020 |
Why?
|
Africa, Eastern | 1 | 2007 | 76 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3586 | 0.020 |
Why?
|
Africa, Western | 1 | 2007 | 159 | 0.020 |
Why?
|
Aged | 4 | 2019 | 168218 | 0.020 |
Why?
|
Rats | 2 | 2000 | 23679 | 0.020 |
Why?
|
Research Design | 2 | 2019 | 6157 | 0.020 |
Why?
|
Venereology | 1 | 2004 | 3 | 0.020 |
Why?
|
Chronic Disease | 1 | 2019 | 9267 | 0.010 |
Why?
|
Urban Population | 1 | 2011 | 2025 | 0.010 |
Why?
|
England | 1 | 2004 | 524 | 0.010 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 557 | 0.010 |
Why?
|
Rural Health | 1 | 2004 | 296 | 0.010 |
Why?
|
Chlamydia trachomatis | 1 | 2004 | 239 | 0.010 |
Why?
|
Asthma | 1 | 2001 | 6172 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 1992 | 2307 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 29742 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12604 | 0.010 |
Why?
|
Counseling | 1 | 2008 | 1541 | 0.010 |
Why?
|
Nimodipine | 1 | 1999 | 56 | 0.010 |
Why?
|
Dizocilpine Maleate | 1 | 1999 | 172 | 0.010 |
Why?
|
Focus Groups | 1 | 2004 | 1384 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 1999 | 378 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 1992 | 3175 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6201 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5070 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2022 | 80168 | 0.010 |
Why?
|
Sex Distribution | 1 | 2001 | 2284 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2008 | 3561 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3245 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3262 | 0.010 |
Why?
|
Child | 1 | 2023 | 79818 | 0.010 |
Why?
|
Neuroprotective Agents | 1 | 1999 | 955 | 0.010 |
Why?
|
San Francisco | 1 | 1992 | 162 | 0.010 |
Why?
|
Clinical Nursing Research | 1 | 1991 | 14 | 0.010 |
Why?
|
Animals | 2 | 2000 | 167768 | 0.010 |
Why?
|
Internal-External Control | 1 | 1991 | 359 | 0.010 |
Why?
|
Cell Survival | 1 | 1999 | 5781 | 0.010 |
Why?
|
Algorithms | 1 | 2008 | 13961 | 0.000 |
Why?
|
Affect | 1 | 1991 | 1480 | 0.000 |
Why?
|
Health Behavior | 1 | 1992 | 2617 | 0.000 |
Why?
|
Quality of Life | 1 | 1991 | 13285 | 0.000 |
Why?
|